CClinicalTrials.gg
CompletedNCT03447613Updated Nov 30, 2018

Retinal Nerve Fiber Layer Thickness and Cerebrospinal Fluid Aβ/Tau

An observational study in Alzheimer Disease, sponsored by Shanghai 10th People's Hospital. Completed at 1 site in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2018-11-30.

Sponsored by Shanghai 10th People's Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
86
Ages
50 Years and older
Sex
All
01

Study summary

To test the hypothesis that retinal nerve fiber layer (RNFL) thickness is correlated with Aβ and Tau concentration of cerebrospinal fluid (CSF) in an older population.

Read the detailed description

retinal nerve fiber layer (RNFL) thickness changing has been reported in Alzheimer's Disease (AD) patients at an early stage, and has been demonstrated as a potential biomarker able to predict cognitive deterioration (Hinton DR et al., N Engl J Med 1986; London A et al. Nat Rev Neurol 2013; Chang LY et al., Alzheimers Dement 2014). However, whether RNFL thickness is correlated with cerebrospinal fluid (CSF) features of AD pathogenesis (e.g., Aβ and Tau) remains unclear. The investigators thus conducted this observational cohort study to test the correlation between RNFL thickness changing and CSF, to further validate RNFL as a potential AD biomarker.

02

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • retinal nerve fiber layer
  • cerebrospinal fluid Aβ and Tau
03

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A total of 300 old adults who were scheduled to have elective total hip or knee replacement surgery, ureteroscopic lithotripsy and transurethral resection of the prostate at the Shanghai 10th People's Hospital were asked to participate in this study. A total of 104 participants were enrolled from August 2013 to December 2014, and the data from 86 participants were finally included in the study.

Inclusion criteria

  1. 50 years old or older;
  2. five years or more of education and scores of MMSE ≥ 24 points;
  3. Chinese as their first language;
  4. Having spinal anesthesia.

Exclusion criteria

Exclusion Criteria:

  1. prior diagnoses of neurologic diseases, e.g., dementia, Parkinson's diseases, multiple sclerosis or stroke according to DSM-IV;
  2. history of mental disorders (e.g., major depressive disorder and schizophrenia) diagnosed according to DSM-IV;
  3. known diseases contributing to the retina pathologies, e.g., diabetes, glaucoma or increased intraocular pressure (more than 22 mmHg), cataract, and macular degeneration and hypermyopia;
  4. unwillingness to comply with the cognitive assessments;
  5. ungradable images of OCT.
04

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
86 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • elderly participants with surgery

    The studied cohort were participants 50 years old or older, without a diagnosis of dementia, and scheduled to have orthopedic or urological surgery under spinal anesthesia at Shanghai 10th People's Hospital.

    Procedure: surgery

Interventions

  • Proceduresurgery

    All participants were scheduled to have elective total hip or knee replacement surgery, ureteroscopic lithotripsy and transurethral resection of the prostate under spinal anesthesia at the Shanghai 10th People's Hospital. After 5 years, the investigaors will follow up the participants including cognitive functions, PET-CT, thickness of Retinal Nerve Fiber Layer.

05

What researchers measure

Primary outcomes

  1. Specific cognitive function

    Neuropsychological test battery to assess specific cognitive function, including immediate memory, visuospatial memory and executive function.

    Time frame: Within one week before surgery

Secondary outcomes

  1. retinal nerve fiber layer (RNFL) thickness

    Optical coherence tomography (Carl Zeiss Meditec, Inc., Dublin, CA, USA) to measure RNFL thickness

    Time frame: Within one week before surgery

  2. Cerebrospinal fluid (CSF) Aβ concentration

    ELISA kits (Aβ40: Cat. # 292-62301; Aβ42: Cat. # 296-64401, Wako, Richmond, VA) to measure Aβ concentration

    Time frame: During the spinal anesthesia before the administration of the local anesthetic.

  3. Cerebrospinal fluid (CSF) Tau concentration

    ELISA kits (Tau: Cat. # KHB0041, Invitrogen, San Francisco, CA) to measure Aβ concentration

    Time frame: During the spinal anesthesia before the administration of the local anesthetic.

  4. Global cognitive state

    Mini-Mental State Examination (MMSE) to assess global cognitive function

    Time frame: Within one week before surgery

06

Study locations

1 site
  • Shanghai 10th People's Hospital
    Shanghai, Shanghai 200072, China
07

References and documents

Publications

  • London A, Benhar I, Schwartz M. The retina as a window to the brain-from eye research to CNS disorders. Nat Rev Neurol. 2013 Jan;9(1):44-53. doi: 10.1038/nrneurol.2012.227. Epub 2012 Nov 20. PubMed 23165340 ↗
  • Chang LY, Lowe J, Ardiles A, Lim J, Grey AC, Robertson K, Danesh-Meyer H, Palacios AG, Acosta ML. Alzheimer's disease in the human eye. Clinical tests that identify ocular and visual information processing deficit as biomarkers. Alzheimers Dement. 2014 Mar;10(2):251-61. doi: 10.1016/j.jalz.2013.06.004. Epub 2013 Sep 5. PubMed 24011928 ↗
  • Hinton DR, Sadun AA, Blanks JC, Miller CA. Optic-nerve degeneration in Alzheimer's disease. N Engl J Med. 1986 Aug 21;315(8):485-7. doi: 10.1056/NEJM198608213150804. PubMed 3736630 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT03447613
Lead sponsor
Shanghai 10th People's Hospital
Collaborators
Massachusetts General Hospital
Responsible party
Yuan Shen, MD, PhD (Chief of Psychiatry Department, Shanghai 10th People's Hospital) — Principal investigator
First posted
Feb 27, 2018
Start date
Aug 1, 2013
Primary completion
Dec 31, 2014
Completion
Dec 31, 2014
Last update
Nov 30, 2018

Study contacts

Yuan Shen, MD, PhD
principal investigator · Shanghai 10th People's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion